|
|
Volumn 29, Issue 6, 2011, Pages 465-466
|
|
First cystic fibrosis drug advances towards approval.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMINOPHENOL DERIVATIVE;
ANTIINFECTIVE AGENT;
ANTIINFLAMMATORY AGENT;
CFTR PROTEIN, HUMAN;
IVACAFTOR;
N-(2,4-DI-TERT-BUTYL-5-HYDROXYPHENYL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE;
QUINOLONE DERIVATIVE;
TRANSMEMBRANE CONDUCTANCE REGULATOR;
CYSTIC FIBROSIS;
DRUG APPROVAL;
DRUG INDUSTRY;
GENETICS;
HUMAN;
METABOLISM;
METHODOLOGY;
MOLECULAR CLONING;
NOTE;
PHARMACOGENETICS;
PHASE 3 CLINICAL TRIAL (TOPIC);
AMINOPHENOLS;
ANTI-BACTERIAL AGENTS;
ANTI-INFLAMMATORY AGENTS;
CLINICAL TRIALS, PHASE III AS TOPIC;
CLONING, MOLECULAR;
CYSTIC FIBROSIS;
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;
DRUG APPROVAL;
DRUG INDUSTRY;
HUMANS;
PHARMACOGENETICS;
QUINOLONES;
|
|
EID: 80054041569
PISSN: None
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0611-465 Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|
